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The development of atherosclerosis is countered by the reverse transport of cholesterol from peripheral
tissues to the liver for excretion. In this issue of Cell Metabolism, Stein et al. (2014) establish LRH-1 as an
important regulator of reverse cholesterol transport and identify SUMOylation as a primary mode of LRH-1
regulation.Nuclear receptors are a class of ligand-
activated transcription factors that play
central roles in the control of metabolism.
The nuclear receptor liver receptor homo-
log 1 (LRH-1, also known as NR5A2) is an
established regulator of hepatic gene
expression. Prior analysis of liver-specific
LRH-1 knockout mice had revealed
altered expression of genes involved in
glucose metabolism, reduced hepatic
glucose uptake, and reduced glycogen
and lipid synthesis (Oosterveer et al.,
2012). LRH-1 had also previously been
shown to affect the expression of genes
involved in cholesterol flux, including
Scarb1, which is involved in HDL uptake
into hepatocytes, and Abcg5 and Abcg8,
which are important for cholesterol excre-
tion into bile (Freeman et al., 2004;
Schoonjans et al., 2002). However, the
physiological significance of this regula-
tionwas unclear. In this issue ofCell Meta-
bolism, Stein et al. (2014) firmly establish
LRH-1 as a determinant of reverse choles-
terol transport and atherosclerosis sus-
ceptibility and also highlight a key role for
posttranslational modification in the con-
trol of LRH-1 function (Stein et al., 2014).
Posttranslational modification of tran-
scription factors can alter their activity
and facilitate the establishment of distinct
transcriptional programs in response to
various stimuli. Reversible modification
of a protein with the small ubiquitin-like
modifier (SUMO) may affect a target pro-
tein’s activity, conformation, and interac-
tions with other proteins (Flotho and
Melchior, 2013). Many nuclear receptors
have been shown to be SUMOylated in
various experimental systems, but few
studies have tested the biological impor-
tance of these modifications in living ani-558 Cell Metabolism 20, October 7, 2014 ª20mals. Previous work showed that LRH-1
can be modified by E3 SUMO ligases on
several lysine residuesand that thesemod-
ifications affect its transcriptional activity.
Stein et al. now identify lysine 289 in
the hinge region of LRH-1, which exists
within a conserved SUMO acceptor motif,
as a biologically important target of
SUMOylation (Stein et al., 2014). When
this lysine is mutated to arginine (K289R),
thereby abolishing SUMOylation, LRH-1
transcriptional activity is increased,
confirming previous studies describing
SUMOylation as a negative regulator of
LRH-1 (Lee et al., 2005). To determine
the physiological relevance of LRH-1
SUMOylation, Stein et al. created an
LRH-1 K289R knockin mouse model. In
line with their in vitro observations, these
mutant mice showed increased expres-
sion of LRH-1 target genes, including
several genes linked to cholesterol ho-
meostasis. In total, the expression of
more than 3,000 genes was altered in the
settingofSUMO-deficient LHR-1knockin.
By contrast, complete loss of LRH-1
expression in the liver altered the expres-
sion of only a few hundred genes. These
data suggest not only that SUMOylation
inhibits LRH-1 transcriptional activity
in vivo, but also that posttranslational
modification may be a primary mecha-
nism by which LRH-1 is regulated. Inter-
estingly, Stein et al. found that only a
subset of genes regulated by LRH-1
are induced with inhibition of LRH-1
SUMOylation, suggesting that this modifi-
cation does not result in a global alteration
of LRH-1 function, but rather may selec-
tively modify specific gene programs.
Consistent with these effects on gene
expression, loss of LRH-1 SUMOylation14 Elsevier Inc.had robust consequences for lipid meta-
bolism. Mice expressing SUMO-deficient
LRH-1 on an atherosclerosis-prone
Ldlr/ background developed fewer
atherosclerotic lesions than control
Ldlr/ mice. Stein et al. link this finding
to increased rates of biliary excretion of
cholesterol, bile acids, and phospholipids
in LRH-1 K289R mice. The ability of an
animal to remove cholesterol through
the reverse cholesterol transport pathway
is known to be an important factor in
atherosclerosis development. Stein et al.
propose that increased expression of
LRH-1 target genes involved in hepatic
reverse cholesterol transport (e.g.,
Abcg5, Abcg8, and Scarb1) is the basis
for the reduction in atherosclerosis
observed in SUMO-deficient LRH-1
knockin mice.
Stein et al. further elucidated a molecu-
lar mechanism for the ability of LRH-1
SUMOylation to affect its transcriptional
output. They found that non-SUMOylated
LRH-1 was no longer able to interact with
PROX1, a transcriptional corepressor ex-
pressed in the liver that has previously
been demonstrated to modify LRH-1
function (Qin et al., 2004). Importantly,
PROX1 was able to repress the transcrip-
tional activity of wild-type LRH-1, but not
the K289R mutant, on specific target
genes involved in reverse cholesterol
transport, including Scarb1, Abcg5, and
Abcg8. These observations support the
conclusion that SUMOylation of LRH-1
and subsequent PROX1 recruitment
inhibits the LRH-1-dependent transcrip-
tion of genes involved in hepatic reverse
cholesterol transport (Figure 1).Moreover,
this mechanism highlights the impor-
tance of posttranslational modification of
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Figure 1. SUMOylation of LRH-1 Promotes Its Interaction with PROX1 and Inhibits Gene
Expression Linked to Reverse Cholesterol Transport
LRH-1 promotes transcription of genes involved in hepatic reverse cholesterol transport including Scarb1,
Abgc5, and Abcg8. Expression of these genes contributes to increased hepatic cholesterol uptake and
excretion. SUMOylation of LRH-1 promotes its interaction with the transcriptional repressor PROX1
and thereby inhibits target gene expression, inhibits reverse cholesterol transport (RCT), and increases
susceptibility to atherosclerosis.
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Overall, the studies of Stein et al. reveal
a critical mechanism for regulation of
LRH-1 function and outline a major phys-
iological role for LRH-1 in the control of
gene expression linked to cholesterol ho-
meostasis (Stein et al., 2014). The work
also raises several interesting questions
for future investigation. For example,
what upstream signaling pathways con-
trol LRH-1 SUMOylation? Is this post-translational modification responsive to
metabolic cues? The proposal that
SUMOylation selectively affects subsets
of LRH-1 targets also deserves further
exploration. For example, LRH-1 has
recently been implicated in the resolution
of ER stress (Mamrosh et al., 2014). Does
SUMOylation impact this facet of LRH-1
function? Finally, prior work has shown
that LRH-1 can bind phospholipid ligands
(Lee et al., 2011). Do these ligands affect
capacity for receptor SUMOylation?Cell Metabolism 2Although there is clearly more to learn
about the function of SUMOylation in
metabolic control, Stein et al. provide an
elegant example of how a single post-
translational protein modification can
affect a complex disease phenotype
such as atherosclerosis. These studies
will undoubtedly propel further research
focused on how posttranslational modi-
fication of nuclear receptors affects
the function of these key metabolic
regulators.REFERENCES
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